AAPL   319.55 (+0.21%)
MSFT   182.87 (-0.35%)
FB   235.07 (+0.07%)
GOOGL   1,435.00 (+1.54%)
NVDA   351.61 (-2.61%)
BABA   202.80 (+1.55%)
MU   46.48 (+3.43%)
GE   6.88 (+7.33%)
TSLA   820.82 (+0.48%)
AMD   54.28 (-1.61%)
ACB   15.73 (-1.75%)
F   5.84 (+3.18%)
GILD   74.15 (+1.09%)
DIS   122.11 (+3.47%)
NFLX   415.19 (-3.29%)
BAC   24.39 (+7.63%)
BA   145.66 (+5.91%)
AAPL   319.55 (+0.21%)
MSFT   182.87 (-0.35%)
FB   235.07 (+0.07%)
GOOGL   1,435.00 (+1.54%)
NVDA   351.61 (-2.61%)
BABA   202.80 (+1.55%)
MU   46.48 (+3.43%)
GE   6.88 (+7.33%)
TSLA   820.82 (+0.48%)
AMD   54.28 (-1.61%)
ACB   15.73 (-1.75%)
F   5.84 (+3.18%)
GILD   74.15 (+1.09%)
DIS   122.11 (+3.47%)
NFLX   415.19 (-3.29%)
BAC   24.39 (+7.63%)
BA   145.66 (+5.91%)
AAPL   319.55 (+0.21%)
MSFT   182.87 (-0.35%)
FB   235.07 (+0.07%)
GOOGL   1,435.00 (+1.54%)
NVDA   351.61 (-2.61%)
BABA   202.80 (+1.55%)
MU   46.48 (+3.43%)
GE   6.88 (+7.33%)
TSLA   820.82 (+0.48%)
AMD   54.28 (-1.61%)
ACB   15.73 (-1.75%)
F   5.84 (+3.18%)
GILD   74.15 (+1.09%)
DIS   122.11 (+3.47%)
NFLX   415.19 (-3.29%)
BAC   24.39 (+7.63%)
BA   145.66 (+5.91%)
AAPL   319.55 (+0.21%)
MSFT   182.87 (-0.35%)
FB   235.07 (+0.07%)
GOOGL   1,435.00 (+1.54%)
NVDA   351.61 (-2.61%)
BABA   202.80 (+1.55%)
MU   46.48 (+3.43%)
GE   6.88 (+7.33%)
TSLA   820.82 (+0.48%)
AMD   54.28 (-1.61%)
ACB   15.73 (-1.75%)
F   5.84 (+3.18%)
GILD   74.15 (+1.09%)
DIS   122.11 (+3.47%)
NFLX   415.19 (-3.29%)
BAC   24.39 (+7.63%)
BA   145.66 (+5.91%)
Log in

NASDAQ:DNLIDenali Therapeutics Income Statement & Balance Sheet

$26.70
+0.73 (+2.81 %)
(As of 05/26/2020 02:05 PM ET)
Add
Compare
Today's Range
$25.88
Now: $26.70
$26.97
50-Day Range
$17.20
MA: $21.94
$25.45
52-Week Range
$12.39
Now: $26.70
$30.41
Volume29,792 shs
Average Volume397,582 shs
Market Capitalization$2.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8

Financials

Denali Therapeutics (NASDAQ:DNLI) Income Statement, Balance Sheet and Cash Flow Statement

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.